GLAUKOS CORPRTN

 GKOSのチャート


 GKOSの企業情報

symbol GKOS
会社名 Glaukos Corp (GLAUKOS CORPRTN)
分野(sector)   
産業(industry)   
業種 医療機器_医療用品_ディストリビュ―タ―   医療関連(Health Care)
概要 グラウコス(Glaukos Corporation)は眼科医療技術会社である。同社は緑内障の治療用製品の開発・商品化を行う。同社はマイクロ侵襲性緑内障手術(MIGS)装置であるiStentを提供する。iStentは、白内障手術中に作られた小さな角膜切開部を通って挿入され、房水を集めて血流に戻す循環チャネルであるシュレム管に配置されたマイクロバイパスステントである。同社はiStent Inject、iStent Supra、iDoseの3つの追加パイプライン製品を開発する。iStent Injectには、自動注入インサータにプリロードされた2つのステントが含まれる。iStent Supraは、目の中の代替排水スペースにアクセスするように設計される。iDoseは、緑内障患者の眼内圧を低下させるために治療レベルの薬物を長期間にわたって連続的に送達するために眼に埋め込まれるように設計された薬物送達システムである。  グロコスは米国の眼科医療機器メ―カ―。失明の一因である緑内障の治療のための製品や技術の商業化に焦点を当てる。同社はMIGS(超低侵襲な緑内障手術)のパイオニア。主要製品は顕微手術に使用されるチタン製極小管(マイクロバイパス・デバイス)の「iStent」で、FDAに認可されている。本社はカリフォルニア州。  Glaukos (www.glaukos.com) is an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases. The company pioneered Micro-Invasive Glaucoma Surgery, or MIGS, to revolutionize the traditional glaucoma treatment and management paradigm. Glaukos launched the iStent, its first MIGS device, in the United States in 2012, its next-generation iStent inject device in the United States in 2018, and most recently, the iStent inject W device in 2020. In corneal health, Glaukos' proprietary suite of single-use, bio-activated pharmaceuticals are designed to strengthen, stabilize and reshape the cornea through a process called corneal collagen cross-linking to treat corneal ectatic disorders and correct refractive conditions. Glaukos is leveraging its platform technology to build a comprehensive and proprietary portfolio of micro-scale surgical and pharmaceutical therapies in glaucoma, corneal health and retinal disease.
本社所在地 229 Avenida Fabricante San Clemente CA 92672 USA
代表者氏名 William J. Link
代表者役職名 Independent Chairman of the Board
電話番号 +1 949-367-9600
設立年月日 35977
市場名 NYSE(ニューヨーク証券取引所)
ipoyear
従業員数 437人
url www.glaukos.com
nasdaq_url
adr_tso
EBITDA (百万ドル) -6.73800
終値(lastsale)
時価総額(marketcap)
時価総額 (百万ドル) 2825.00300
売上高 (百万ドル) 181.27800
企業価値(EV) (百万ドル) 2684.51500
当期純利益 (百万ドル) -12.95100
決算概要 BRIEF: For the fiscal year ended 31 December 2018 Glaukos Corp revenues increased 14% to $181.3M. Net loss increased from $92K to $13M. Revenues reflect International segment increase of 61% to $29.6M United States segment increase of 8% to $151.7M. Higher net loss reflects Selling general and administrative increase of 20% to $99.7M (expense) Research and development increase of 27% to $44.5M (expense).

 GKOSのテクニカル分析


 GKOSのニュース

   Glaukos Corporation PT Raised to $54 at Citi  2022/08/04 11:10:05 Investing.com
https://www.investing.com/news/pro/glaukos-corporation-pt-raised-to-54-at-citi-432SI-2863376
   Glaukos Corporation (GKOS) CEO Tom Burns on Q2 2022 Results Earnings Call Transcript  2022/08/04 01:36:06 Seeking Alpha
Glaukos Corporation (NYSE:NYSE:GKOS) Q2 2022 Earnings Conference Call August 03, 2022 04:30 PM ET Company Participants Chris Lewis - VP, IR and Corporate Affairs Tom Burns - Chairman and…
   Recap Of Wednesday''s Biotech Catalysts - End Of the Day Summary  2022/08/03 22:24:06 Benzinga
The U.S. Food and Drug Administration (FDA) has accepted for review MediWound ’s (NASDAQ: MDWD ) recently re-submitted Biologics License Application (BLA) for its lead asset NexoBrid for eschar removal (debridement) in adults with deep partial-thickness and/or full-thickness thermal burns. MediWound shares traded in a range of $1.6 to $1.76 on a day volume of 283.18 thousand shares, closed regular trading session at $1.67. The company shares are currently trading at $1.77, up 5.99 percent in the after-hours trading session. Alnylam (NASDAQ: ALNY ) announced positive results from the APOLLO-B Phase 3 study of Patisiran for the treatment of transthyretin-mediated (ATTR) amyloidosis with cardiomyopathy. Alnylam shares traded in a range of $198 to $220.92 on a day volume of 8.54 million shares, closed regular trading session at $212.01. The U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for Glaukos ’ (NYSE: GKOS ) iStent infinite Trabecular Micro-Bypass System indicated for use in a standalone procedure to reduce elevated intraocular pressure (IOP) in patients with primary open-angle glaucoma uncontrolled by prior medical and surgical therapy.
   Glaukos: Q2 Earnings Insights  2022/08/03 22:12:26 Benzinga
Glaukos (NYSE: GKOS ) reported its Q2 earnings results on Wednesday, August 3, 2022 at 04:00 PM. Here''s what investors need to know about the announcement. Earnings Glaukos missed estimated earnings by 88.64%, reporting an EPS of $-0.83 versus an … Full story available on Benzinga.com
   Glaukos Non-GAAP EPS of -$0.83 misses by $0.39, revenue of $72.69M beats by $4.7M (NYSE:GKOS)  2022/08/03 20:51:51 Seeking Alpha
Glaukos press release (GKOS): Q2 Non-GAAP EPS of -$0.83 misses by $0.39.Revenue of $72.69M (-6.9% Y/Y) beats by $4.7M.The company expects 2022 net sales to be in the range of…
   Glaukos (GKOS) Investor Presentation - Slideshow (NYSE:GKOS)  2022/06/04 14:54:16 Seeking Alpha
The following slide deck was published by Glaukos Corporation in conjunction with this event.
   Glaukos Announces Participation in the William Blair Growth Stock Conference  2022/06/02 11:00:00 Business Wire
SAN CLEMENTE, Calfi.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its management is scheduled to participate in the William Blair 42nd Annual Growth Stock Conference on Wednesday, June 8, 2022, at 8:40 a.m. CT in Chicago, IL. A live and archived webcast for this event will be available in the Investors section o
   Glaukos Corporation (GKOS) CEO Tom Burns on Q1 2022 Results - Earnings Call Transcript  2022/05/04 23:48:02 Seeking Alpha
Glaukos Corporation (NYSE:NYSE:GKOS) Q1 2022 Earnings Conference Call May 4, 2022, 4:30 PM ET Company Participants Tom Burns – Chairman & Chief Executive Officer Joe Gilliam – President…
   Glaukos Non-GAAP EPS of -$0.38 beats by $0.13, revenue of $67.7M beats by $6.85M  2022/05/04 20:16:39 Seeking Alpha
Glaukos press release (NYSE:GKOS): Q1 Non-GAAP EPS of -$0.38 beats by $0.13.Revenue of $67.7M (-0.4% Y/Y) beats by $6.85M.
   Glaukos Corporation Announces First Quarter 2022 Financial Results  2022/05/04 20:05:00 Business Wire
SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced financial results for the first quarter ended March 31, 2022. Key highlights include: Net sales of $67.7 million in Q1 2022. Glaucoma net sales of $51.5 million and Corneal Health net sales of $16.1 million in Q1 2022. Gross margin of approximately 75%
   Glaukos Corporation to Release Fourth Quarter and Full Year 2021 Financial Results after Market Close on February 22  2022/02/01 12:00:00 Kwhen Finance
   Glaukos'' iDose TR Shows Sustained Reduction In Ocular Pressure, Favorable Safety Profile  2022/01/12 10:47:43 Benzinga
Ophthalmic medical company Glaukos Corporation (NYSE: GKOS ) announced data from the Phase 2b trial of iDose TR, a sustained-release travoprost implant. The data showed sustained and substantial reductions in intraocular pressure (IOP) in a 36-month analysis. The iDose TR contains formulated travoprost, a prostaglandin analog to reduce IOP. 70% and 68% of subjects in the fast- and slow-release iDose TR Full story available on Benzinga.com
   Glaukos gets 510(k) clearance from FDA for iPRIME viscodelivery system  2022/01/06 21:24:39 Seeking Alpha
Glaukos (GKOS) receives 510(k) clearance from the FDA for its iPRIME viscodelivery system
   Glaukos Announces Participation in the J.P. Morgan Healthcare Conference  2021/12/29 12:00:00 Kwhen Finance
   Glaukos Co. (NYSE:GKOS) Shares Bought by Stephens Inc. AR  2021/12/24 09:24:41 Dakota Financial News
Stephens Inc. AR lifted its holdings in Glaukos Co. (NYSE:GKOS) by 80.3% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 5,922 shares of the medical instruments suppliers stock after purchasing an additional 2,638 shares during the period. Stephens Inc. ARs holdings in []

 関連キーワード  (医療機器_医療用品_ディストリビュ―タ― 米国株 GLAUKOS CORPRTN GKOS )

医療で使われる機器のこと。レントゲン装置やからだの断面を画像化できるMRI(磁気共鳴画像)装置など高機能機器を含め数多くの種類がある。医療現場で使われるため、正確で精密である点などが求められる。医療機器への需要は着実に高まっており、電機メーカーなどからの進出も進んでいる。

 twitter  (公式ツイッターやCEOツイッターなど)